Abstract
Mesenchymal stem cells (also known as multipotent stromal cells, MSCs) are considered as promising candidate cells for stem cell-based therapy. However, the applications of MSCs are facing controversial concerns of potential tumorigenic risks. There is also increasing evidence that MSCs may play a modulatory role in the development and progression of tumors. MSCs have the potential to migrate to tumor sites and promote tumor cell proliferation, invasion and metastasis. In addition to these risks, MSCs also have shown to be an attractive target for gene/cell-mediated anti-tumor therapy. These complicated behaviors of MSCs in cancer warrant further study to evaluate the benefits of MSCs treatment and the long-term risk of tumor origin or incidence from MSCs under different pathological conditions.
Keywords: Mesenchymal stem cells (MSCs), malignant transformation, tumor associated fibroblasts (TAF), tumor growth and metastasis, antitumor therapy, tumorigenic risks, tumor cell proliferation, gene/cell-mediated anti-tumor therapy, Tumor Stromal Cells.
Current Stem Cell Research & Therapy
Title:Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Volume: 7 Issue: 5
Author(s): Dechun Wang, Shuguang Wang and Chunmeng Shi
Affiliation:
Keywords: Mesenchymal stem cells (MSCs), malignant transformation, tumor associated fibroblasts (TAF), tumor growth and metastasis, antitumor therapy, tumorigenic risks, tumor cell proliferation, gene/cell-mediated anti-tumor therapy, Tumor Stromal Cells.
Abstract: Mesenchymal stem cells (also known as multipotent stromal cells, MSCs) are considered as promising candidate cells for stem cell-based therapy. However, the applications of MSCs are facing controversial concerns of potential tumorigenic risks. There is also increasing evidence that MSCs may play a modulatory role in the development and progression of tumors. MSCs have the potential to migrate to tumor sites and promote tumor cell proliferation, invasion and metastasis. In addition to these risks, MSCs also have shown to be an attractive target for gene/cell-mediated anti-tumor therapy. These complicated behaviors of MSCs in cancer warrant further study to evaluate the benefits of MSCs treatment and the long-term risk of tumor origin or incidence from MSCs under different pathological conditions.
Export Options
About this article
Cite this article as:
Wang Dechun, Wang Shuguang and Shi Chunmeng, Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies, Current Stem Cell Research & Therapy 2012; 7 (5) . https://dx.doi.org/10.2174/157488812802481454
DOI https://dx.doi.org/10.2174/157488812802481454 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reactive Oxygen-Induced Cardiac Intracellular Pathways During Ischemia and Reperfusion
Current Signal Transduction Therapy ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Recent Patents on Oral Combination Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]
Current Vascular Pharmacology Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An <i>In-silico</i> Study
Current Pharmaceutical Design A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Amino Acid and Polyamine Membrane Transporters in Trypanosoma cruzi: Biological Function and Evaluation as Drug Targets
Current Medicinal Chemistry New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design